The Latest Breaking News from Crispr Therapeutics

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

ARK Innovation, the flagship Cathie Wood ETF, is skidding in 2024 as the S&P 500 hits a record high. Blame Coinbase, Tesla and other big ARKK ETF holdings.

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

The FDA could approve Crispr Therapeutics' gene-edited sickle cell treatment as early as December. In response, CRSP stock surged Friday.

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

A Relative Strength Rating upgrade for CRISPR Therapeutics shows improving technical performance.

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.37%. U.S. stock index futures this morning are moderately higher after U.S. Mar producer prices rose less than expected, easing inflation concerns. Also, weekly jobless claims rose...